Evidence map›Paper›PMID 37685923›Full record

ArticleInternational journal of molecular sciences2023

Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer.

Iris J M Levink, Maurice P H M Jansen, Zakia Azmani, Wilfred van IJcken, Ronald van Marion, Maikel P Peppelenbosch, Djuna L Cahen, Gwenny M Fuhler, Marco J Bruno

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Iris J M LevinkDepartment of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-9825-8728
Maurice P H M JansenDepartment of Medical Oncology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.
Zakia AzmaniCenter for Biomics, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.
Wilfred van IJckenCenter for Biomics, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-0421-8301
Ronald van MarionDepartment of Pathology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-6642-3856
Maikel P PeppelenboschDepartment of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-9112-6028
Djuna L CahenDepartment of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-6753-4857
Gwenny M FuhlerDepartment of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-9221-4855
Marco J BrunoDepartment of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands.
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular profiling may enable earlier detection of pancreatic cancer (PC) in high-risk individuals undergoing surveillance and allow for personalization of treatment. We hypothesized that the detection rate of DNA mutations is higher in pancreatic juice (PJ) than in plasma due to its closer contact with the pancreatic ductal system, from which pancreatic cancer cells originate, and higher overall cell-free DNA (cfDNA) concentrations. In this study, we included patients with pathology-proven PC or intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia (HGD) from two prospective clinical trials (KRASPanc and PACYFIC) for whom both PJ and plasma were available. We performed next-generation sequencing on PJ, plasma, and tissue samples and described the presence (and concordance) of mutations in these biomaterials. This study included 26 patients (25 PC and 1 IPMN with HGD), of which 7 were women (27%), with a median age of 71 years (IQR 12) and a median BMI of 23 kg/m

Indexed as

Cell-Free Nucleic AcidsPancreatic Intraductal NeoplasmsPancreatic NeoplasmsBiocompatible MaterialsChildFemaleHumansMalePancreatic JuiceProspective StudiesProto-Oncogene Proteins p21(ras)Biocompatible MaterialsCell-Free Nucleic AcidsProto-Oncogene Proteins p21(ras)biomarkerscell-free DNA (cfDNA)circulating tumor DNA (ctDNA)detectiondiagnosisDNAKRASliquid biopsymutationpancreatic cancerpancreatic juiceplasmaprecision medicineSMAD4TP53

Identifiers

PMID37685923
PMCPMC10487634
OpenAlexW4386098200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.